Description: Starpharma Holdings Limited is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company utilizes dendrimers, which is a type of synthetic nanoscale polymer that is regular in size and structure and suited to pharmaceutical and medical uses. It has approximately three development programs, including VivaGel portfolio, DEP drug delivery and agrochemicals. It develops and commercializes dendrimer nanotechnology across various applications, including sexual health, drug delivery for pharmaceuticals, animal health, coatings and inks, crop protection and agrochemicals, diagnostics and research reagents, cosmetics and water treatment. Its products are based on VivaGel (SPL7013, astodrimer sodium), a dendrimer, which has antimicrobial properties. It has both partnered and internal programs in drug delivery. In agrochemicals, it has partnerships with Adama, as well as internal programs, including an enhanced version of glyphosate.
Home Page: starpharma.com
SPL Technical Analysis
4-6 Southampton Crescent
Abbotsford,
VIC
3067
Australia
Phone:
61 3 8532 2700
Officers
| Name | Title |
|---|---|
| Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA | CEO, MD & Exec. Director |
| Mr. Nigel J. Baade B.Com, Grad. Dip., CPA | CFO & Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 312.5 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3088 |
| Price-to-Sales TTM: | 39.6021 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 50 |